Baquerizo Nole KL, Yim E, Keri JE Probiotics and prebiotics in dermatology. J Am Acad Dermatol. 2014 Oct;71(4):814-21. doi: 10.1016/j.jaad.2014.04.050. Epub 2014 Jun 4. Review.
Dailey HA, Gerdes S, Dailey TA, Burch JS, Phillips JD Noncanonical coproporphyrin-dependent bacterial heme biosynthesis pathway that does not use protoporphyrin. Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2210-5. doi: 10.1073/pnas.1416285112. Epub 2015 Feb 2.
Gribbon EM, Cunliffe WJ, Holland KT Interaction of Propionibacterium acnes with skin lipids in vitro. J Gen Microbiol. 1993 Aug;139(8):1745-51.
Johnson T, Kang D, Barnard E, Li H Strain-Level Differences in Porphyrin Production and Regulation in Propionibacterium acnes Elucidate Disease Associations. mSphere. 2016 Feb 10;1(1). pii: e00023-15. doi: 10.1128/mSphere.00023-15. eCollection 2016 Jan-Feb.
Kang D, Shi B, Erfe MC, Craft N, Li H Vitamin B12 modulates the transcriptome of the skin microbiota in acne pathogenesis. Sci Transl Med. 2015 Jun 24;7(293):293ra103. doi: 10.1126/scitranslmed.aab2009.
Kasimatis G, Fitz-Gibbon S, Tomida S, Wong M, Li H Analysis of complete genomes of Propionibacterium acnes reveals a novel plasmid and increased pseudogenes in an acne associated strain. Biomed Res Int. 2013;2013:918320. doi: 10.1155/2013/918320. Epub 2013 May 13.
Kishishita M, Ushijima T, Ozaki Y, Ito Y New medium for isolating propionibacteria and its application to assay of normal flora of human facial skin. Appl Environ Microbiol. 1980 Dec;40(6):1100-5.
Kjeldstad B, Johnsson A, Sandberg S Influence of pH on porphyrin production in Propionibacterium acnes. Arch Dermatol Res. 1984;276(6):396-400.
Kwon HH, Suh DH Recent progress in the research about Propionibacterium acnes strain diversity and acne: pathogen or bystander? Int J Dermatol. 2016 Nov;55(11):1196-1204. doi: 10.1111/ijd.13282. Review.
Lomholt HB, Kilian M Population genetic analysis of Propionibacterium acnes identifies a subpopulation and epidemic clones associated with acne. PLoS One. 2010 Aug 19;5(8):e12277. doi: 10.1371/journal.pone.0012277.
McDowell A, Nagy I, Magyari M, Barnard E, Patrick S The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution. PLoS One. 2013 Sep 13;8(9):e70897. doi: 10.1371/journal.pone.0070897. eCollection 2013.
Shu M, Kuo S, Wang Y, Jiang Y, Liu YT, Gallo RL, Huang CM Porphyrin metabolisms in human skin commensal Propionibacterium acnes bacteria: potential application to monitor human radiation risk. Curr Med Chem. 2013;20(4):562-8. Review.
Tomida S, Nguyen L, Chiu BH, Liu J, Sodergren E, Weinstock GM, Li H Pan-genome and comparative genome analyses of propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome. mBio. 2013 Apr 30;4(3):e00003-13. doi: 10.1128/mBio.00003-13.
Walsh TR, Efthimiou J, Dréno B Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect Dis. 2016 Mar;16(3):e23-33. doi: 10.1016/S1473-3099(15)00527-7. Epub 2016 Feb 5. Review.
Wei EX, Kirsner RS, Eaglstein WH End points in dermatologic clinical trials: A review for clinicians. J Am Acad Dermatol. 2016 Jul;75(1):203-9. doi: 10.1016/j.jaad.2016.01.052. Epub 2016 Feb 28. Review.
A Phase 1B Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.